69 related articles for article (PubMed ID: 19672256)
21. The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.
Rolff HC; Christensen IJ; Svendsen LB; Wilhelmsen M; Lund IK; Thurison T; Høyer-Hansen G; Illemann M; Nielsen HJ;
J Surg Oncol; 2019 Dec; 120(8):1404-1411. PubMed ID: 31646652
[TBL] [Abstract][Full Text] [Related]
22. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
[TBL] [Abstract][Full Text] [Related]
23. A new assay for measurement of the liberated domain I of the urokinase receptor in plasma improves the prediction of survival in colorectal cancer.
Thurison T; Lomholt AF; Rasch MG; Lund IK; Nielsen HJ; Christensen IJ; Høyer-Hansen G
Clin Chem; 2010 Oct; 56(10):1636-40. PubMed ID: 20802096
[TBL] [Abstract][Full Text] [Related]
24. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
25. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
Levin B; Lieberman DA; McFarland B; Smith RA; Brooks D; Andrews KS; Dash C; Giardiello FM; Glick S; Levin TR; Pickhardt P; Rex DK; Thorson A; Winawer SJ; ; ;
CA Cancer J Clin; 2008; 58(3):130-60. PubMed ID: 18322143
[TBL] [Abstract][Full Text] [Related]
26. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian endoscopy study group on colorectal cancer detection.
Nielsen HJ; Brünner N; Frederiksen C; Lomholt AF; King D; Jørgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Christensen IJ; ;
Scand J Gastroenterol; 2008; 43(2):242-8. PubMed ID: 18224568
[No Abstract] [Full Text] [Related]
27. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.
Ransohoff DF
J Clin Epidemiol; 2007 Dec; 60(12):1205-19. PubMed ID: 17998073
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review.
Burch JA; Soares-Weiser K; St John DJ; Duffy S; Smith S; Kleijnen J; Westwood M
J Med Screen; 2007; 14(3):132-7. PubMed ID: 17925085
[TBL] [Abstract][Full Text] [Related]
29. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
30. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Holinski-Feder E; Klapdor R; Lamerz R; Peltomaki P; Sturgeon C; Topolcan O
Eur J Cancer; 2007 Jun; 43(9):1348-60. PubMed ID: 17512720
[TBL] [Abstract][Full Text] [Related]
31. Estimates of the cancer incidence and mortality in Europe in 2006.
Ferlay J; Autier P; Boniol M; Heanue M; Colombet M; Boyle P
Ann Oncol; 2007 Mar; 18(3):581-92. PubMed ID: 17287242
[TBL] [Abstract][Full Text] [Related]
32. Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
Hewitson P; Glasziou P; Irwig L; Towler B; Watson E
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001216. PubMed ID: 17253456
[TBL] [Abstract][Full Text] [Related]
33. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T; Haese A; Huland H; Steuber T; Christensen IJ; Brünner N; Danø K; Høyer-Hansen G; Lilja H
Clin Chem; 2006 May; 52(5):838-44. PubMed ID: 16543389
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Almasi CE; Høyer-Hansen G; Christensen IJ; Danø K; Pappot H
Lung Cancer; 2005 Jun; 48(3):349-55. PubMed ID: 15893003
[TBL] [Abstract][Full Text] [Related]
35. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activation and cancer.
Danø K; Behrendt N; Høyer-Hansen G; Johnsen M; Lund LR; Ploug M; Rømer J
Thromb Haemost; 2005 Apr; 93(4):676-81. PubMed ID: 15841311
[TBL] [Abstract][Full Text] [Related]
37. Global cancer statistics, 2002.
Parkin DM; Bray F; Ferlay J; Pisani P
CA Cancer J Clin; 2005; 55(2):74-108. PubMed ID: 15761078
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer.
Weitz J; Koch M; Debus J; Höhler T; Galle PR; Büchler MW
Lancet; 2005 Jan 8-14; 365(9454):153-65. PubMed ID: 15639298
[TBL] [Abstract][Full Text] [Related]
39. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
